antibody

Insulin-Like Growth Factor I Receptor, phosphorylated (Tyr1135/1136) Insulin Receptor (Tyr1150/1151) (IGF1R)

I7661-20B

100 ul

monoclonal

domestic rabbit

nonconjugated

phosphorylated

5i120(19H7)

Insulin-Like Growth Factor I Receptor, phosphorylated (Tyr1135/1136) Insulin Receptor (Tyr1150/1151) (IGF1R)

rabbit

Mab

Phosphorylated

Antibodies

100 ul

5i120(19H7)

IgG

Type I insulin-like growth factor receptor IGF-IR), a transmembrane tyrosine kinase, is widely expressed among many cell types in fetal and postnatal tissues, as well as many cell lines (1–3). Upon binding of its ligands, IGF-I and IGF-II, autophosphorylation of receptors occurs. The triple tyrosine cluster (Tyr1131, Tyr1135 and Tyr1136) within the kinase domain is the earliest major site of autophosphorylation (4). Phosphorylation of these three tyrosine residues is necessary for kinase activation (5,6). Insulin receptors (IRs) share significant similarity with IGF-I receptors in both structure and function. There is also an equivalent triple tyrosine cluster (Tyr1146, Tyr1150 and Tyr1151) in the activation loop of the kinase domain. Tyrosine autophosphorylation of the receptors is one of the earliest cellular responses to insulin stimulation (7). The autophosphorylation begins by phosphorylation of Tyr1146 and either Tyr1150 or Tyr1151. The full activation of receptor kinase activity depends on the triple tyrosine phosphorylation (8). Applications: Suitable for use in Western Blot. Other applications not tested. Recommended Dilution: Western Blot: 1:1000 Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot. Store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Hu Mo Rt

Synthetic phosphopeptide corresponding to residues surrounding Tyr1135/1136 of human IGF-I receptor. Species sequence homology: bovine and canine

Detects endogenous levels of IGF-I receptor and insulin receptor only when phosphorylated at tyrosine1135/1136 or tyrosine 1150/1151, respectively. It does not cross-react with other related tyrosine-phosphorylated tyrosine kinases. Species Crossreactivity: Human, rat and mouse

Serum

Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 50% glycerol.

Not determined

Product Type: Mab Isotype: IgG Clone No: 5i120(19H7) Host: rabbit Source: human Concentration: Not determined Form: Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 50% glycerol. Purity: Serum Immunogen: Synthetic phosphopeptide corresponding to residues surrounding Tyr1135/1136 of human IGF-I receptor. Species sequence homology: bovine and canine Specificity: Detects endogenous levels of IGF-I receptor and insulin receptor only when phosphorylated at tyrosine1135/1136 or tyrosine 1150/1151, respectively. It does not cross-react with other related tyrosine-phosphorylated tyrosine kinases. Species Crossreactivity: Human, rat and mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

WB

-20°C

(1) Adams, T.E. et al. (2000) Cell. Mol. Life Sci. 57, 1050–1093. (2) Baserga, R. et al. (2000) Oncogene 19, 5574–5581. (3) Scheidegger, K.J. et al. (2000) J. Biol. Chem. 275, 38921–38928. (4) Hernandez-Sanchez, C. et al. (1995) J. Biol. Chem. 270, 29176–29181. (5) Lopaczynski, W. et al. (2000) Biochem. Biophys. Res. Commun. 279, 955–960. (6) Baserga, R. et al. (1999) Exp. Cell Res. 253, 1–6. (7) White, M.F. et al. (1985) J. Biol. Chem. 260, 9470–9478. (8) White, M.F. et al. (1988) J. Biol. Chem. 263, 2969–2980. General References: 1. Spieker-Polet H, et al. Proc Natl Acad Sci. 1995 Sep 26;92(20):9348-52. 2. Liguori MJ, et al. Hybridoma. 2001 Jun; 20(3):189-98. 3. G.Cano1, F. Milanezi2, D. Leitao2,3, S. Ricardo2, M.J. Brito1, F. C. Schmitt2-3 1Garcia da Orta Hospital, Almada, Portugal,2 Inst. Molec. Pathology and Immunology of Porto University, Portugal,3 Medical Faculty of Porto university, Portugal Diagn Cytopathol, 2003 Oct; 29(4): 207 -11. 4. L.K. Diaz* and N.Sneige *Department of Pathology,Northwestern University, Chicago,+ Department of Pathology, University of Texas, Huston, Adv Anat Pathol,2005; 12(1), 10-19. 5. Z. Huang1, W. Zhu2, G. Szekeres3, H. Xia1 1Spring Bioscience Corp, Fremont,CA, 2 Epitomics Inc, Burlingame,CA, , 4Histopathology Ltd, Hungary, Appl Immunohistochem Mol Morphol. 2005; 13 (1): 91-95 6. S. Rossi1, E. Orvieto1, S.Chinellato1, A. Furlanetto1, L.Laurino1, F. Facchetti2, AP Dei Tos 2 1Department of Pathology, 2Treviso, Italy; *Brescia, University School of Medicine, Brescia, Italy., Abstract presented at USCAP 2004. Modern Pathology 2004; 17 (suppl 1): 361A 7. M. Blechner, E. Ballesteros, D. Mandich, D. Stevens, R. Cartun, Hartford Hospital, Hartford, CT. Abstract presented at USCAP 2004. Modern Pathology 2004; 17 (suppl 1): 241A 8. W. Cheuk, K.O.Y. Wong, C.S.C. Wong and J.K.C. Chan, Department of Pathology, Queen Elizabeth Hospital, Hong Kong, Am J Surg Path, 2004; 28 (6): 801-807. 9. G.B. Budd, E. Tso, B. Yoder, T. Choueiri, P. Elson, S. Tarr, M. Skacel, R. Tubbs, A. Dawson, D. Hicks, Cleveland Clinic Foundation, Cleveland, OH, Abstract presented at ASCO Annual meeting, June 2004, New Orleans 10. S. M. Tarr, S. Short, K. Hansen, T. Morken, H. Xia, E. Downs-Kelly, R. R. Tubbs, D. G. Hicks, Department of Pathology and Laboratory Medicine. The Cleveland Clinic Foundation, Cleveland, Ohio. Lab Vision Corp., Fremont, Ca., Spring Bioscience Corp, Fremont ,CA, Abstract presented at Association for Molecular Pathology meeting, Los Angeles, 2004 11. A.M. Gown, T.S. Barry, P. Kandalaft, L.C. Goldstein, C.C. Tse and D.O. Treaba, Clinical Research Division , PhenoPath Laboratories and IMPRIS, Seattle, WA, Abstract presented at USCAP 2005. Modern Pathology 2005; 18, suppl.1,pag 35A 12. D.O. Treaba, A.W. Hing, L.C. Goldstein, T.S. Barry, P. Kandalaft, C.B. Gilks, T.O. Nielsen and A.M. Gown, Clinical Research Division , PhenoPath Laboratories and IMPRIS, Seattle, WA, USA Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada, Abstract presented at USCAP 2005. Modern Pathology 2005; 18, suppl.1,pag 53A 13. S. Rossi1, L. Laurino1, A. Furlanetto1, S.Chinellato1, E. Orvieto1, F. Canal1, F. Facchetti2, A.P. Dei Tos1 1 Depart. Pathology, Hospital of Treviso, Italy, 2 Brescia University School of Medicine, Brescia, Italy, Am J Clin Pathol, 2005, Aug;124(2):295-302

https://usbio-images.r.worldssl.net/prodimages/4/I7661-20B_1.jpg